Lunsumio for Follicular Lymphoma User Reviews
See also:
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
Learn more about Follicular Lymphoma
Care guides
More about Lunsumio (mosunetuzumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
"I've had 4 treatments, 1mg, 2mg, and 2 - 60mg. I've been extremely tired after the two 60mg treatments. Unable to stand without assistance for a few days after treatment. Could not read or comprehend my daily readings. After 12 days from my last treatment, I am just now beginning to be able to take walks and short hikes. I intend to take two more 30mg treatments and then stop so I can enjoy a two-week trip to Hawaii. Upon returning in mid-June, I will meet with my oncologist and the City of Hope doctors for further evaluation and treatment."